Complement-dependent cytotoxic antibodies to human T lymphotropic virus type I (HTLV-I)-infected cells in the sera of HTLV-I-infected individuals

Clinical and Experimental Immunology

Volumn 105, Issue 1, 1996, Pages 39-45

  Plotnicky Gilquin, H ^a,c   Afani, A ^a   Vernant, J C ^b   Desgranges, C ^a  

^a INSERM   (France)

^b CHU La Meynard   (France)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

antibodies; complement; cytolysis; HIV 1; HTLV I

Indexed keywords

AMINO ACID; ANTIBODY; CD3 ANTIGEN; CD4 ANTIGEN; COMPLEMENT; EDETIC ACID; EGTAZIC ACID; EPITOPE; GLYCOPROTEIN; IMMUNOGLOBULIN G; SYNTHETIC PEPTIDE; VIRUS ANTIGEN;

ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; PRIORITY JOURNAL; SERUM; SPASTIC PARAPLEGIA; SPINAL CORD DISEASE; T CELL LEUKEMIA;

EID: 0030035214     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.d01-736.x     Document Type: Article

References (42)

1. Banapour B, Sernatinger J, Levy JA. The AIDS-associated retrovirus is not sensitive to lysis or inactivation by human serum. Virology 1986:152:268-71.
2. Harada S, Yoshiyama H, Yamamoto N. Effects of heat and fresh human serum on the infectivity of human T-lymphotropic virus type III evaluated with new bioassay systems. J Clin Microbiol 1985:22:908-11.
3. Ebenbichler CF, Thielens NM, Vornhagen R, Marschang P, Arlaud GJ, Dierich MP. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J Exp Med 1991;174:1417-24.
4. Yefenof E, Asjö B, Klein E. Alternative complement pathway activation by HIV infected cells: C3 fixation does not lead to complement lysis but enhances NK sensitivity. Int Immunol 1991;3:395-401.
5. Sölder BM, Schulz TF, Hengster P et al. HIV and HIV-infected cells differentially activate the human complement system independent of antibody. Immunol Letters 1989;22:135-46.
6. Marshang P, Gürtler L, Tötsch M, Thielens NM, Arlaud GT, Hittmair A, Katinger H, Dierich MP. HIV-1 and HIV-2 isolates differ in their ability to activate the complement system on the surface of infected cells. AIDS 1993;7:903-10.
7. Spear GT, Sullivan L, Landay AL, Lint TF. Neutralization of human immunodeficiency virus type 1 by complement occurs by viral lysis. J Virol 1990;64:5869-73.
8. Spear GT, Takefman DM, Sullivan BL, Landay AL, Zolla-Pazner S. Complement activation by human monoclonal antibodies to human immunodeficiency virus. J Virol 1993;67:53-59.
9. Nara PL, Robey WG, Gonda MA, Carter SG, Fischinger PJ. Absence of cytotoxic antibody to human immunodeficiency virus-infected cells in humans and its induction in animals after infection of immunizations with purified envelope glycoprotein gp120. Proc Natal Acad Sci USA 1987;84:3797-801.
10. Toth FD, Kiss J, Szabo B, Füst G, Ujhely E, Hollan SR, Vaczi L. Complement-dependent cytotoxicity of antibodies reactive with HIV-induced cell surface antigens in HIV-carrying haemophiliacs. Acta Virol 1989;33:521-6.
11. Szabo B, Locardi C, Lo Presti E, Belardelli F, Benedetto A. Tumor necrosis factor-α increases the sensitivity of human immunodeficiency virus (HIV)-infected monocytic U937 cells to the complement-dependent cytotoxicity of sera from HIV type 1-infected individuals; role of the gp120 protein. J Gen Virol 1993;74:1271-6.
12. Ohkawa S, Wilson LA, Larosa G, Javaherian K, Martin LN. Murphey-Corh MA. Immune responses induced by rpototype vaccines for AIDS in rhesus monkeys. AIDS Res Hum Retrovir 1994;10:27-37.
13. Poiesz BJ, Ruscetti FW, Gazdar AF, Bunn PA, Minna JD, Gallo RC. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci USA 1980;77:7415-9.
14. Yoshida M, Miyoshi I, Hinuma Y. Isolation and characterisation of retroviruses from cell lines of human adult T cell leukemia and its implication in the disease. Proc Natl Acad Sci USA 1982;79:2031-5.
15. Gessain A, Varin E, Vernant JC. Antibodies to human T lymphotropic virus type 1 in patients with tropical spastic paraparesis. Lancet 1985;1:407-10.
16. Osame M, Usuku K, Izumo S, Ijichi N, Amitani H, Igata A, Matsumoto M, Tara M. HTLV-I associated myeloptathy, a new clinical identity. Lancet 1986;1:1031-2.
17. Spear GT, Jiang H, Sullivan BL, Dittel B, Lint TF. Direct binding of complement component Clq to human immunodeficiency virus (HIV) and human T lymphotropic virus type 1 (HTLV-I) coinfected cells. AIDS Res Hum Retrovir 991;7:579-85.
18. Spear GT, Landay AL, Sullivan BL, Dittel B, Lint TF. Activation of complement on the surface of cells infected by human immunodeficiency virus. J Immunol 1990;144:1490-6.
19. Matsushita S, Robert-Guroff M, Trepel J, Cossman J, Mitsuya H, Broder S. Human monoclonal antibody directed against an envelope glycoprotein of human T-cell leukemia virus type 1. Proc Natl Acad Sci USA 1986;83:2672-6.
20. Miyoshi I, Kubonishi I, Yoshimoto S, Akagi T, Ohtsuki Y, Shiraishi Y, Nagata K, Hinuma Y. Type-C virus particles in a cord T-cell line derived by cocultivating normal human cord leukocytes and human leukaemic T cells. Nature (London) 1981;294:770-1.
21. Popovic M, Sarin P, Robert-Guroff M, Kalyaranama V, Mann D, Minowada J, Gallo RC. Isolation and transmission of human retrovirus (human T-cell leukemia virus). Science 1983;219:856-9.
22. Salahuddin SZ, Markham PD, Wrong-Staal F, Franchini G, Kalyanaran VS, Gallo RC. Restricted expressionof human T-cell leukemia-lymphoma virus (HTLV-I) in transformed human umbilical cord blood lymphocytes. Virology 1983;129:51-64.
23. Plotnicky H, Cyblat D, Vernant JC, Desgranges C. Il-2-dependent HTLV-I-infected T cells escape from non-specific, MHC-unfrestricted cellular cytotoxieity. Clin Immunol Immunopathol 1994;73:205-14.
24. Popovic M, Sangadharan MG, Read E, Gallo RC, Detection, isolation and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. Science 1984;224:497-500.
25. Noraz N, Verrier B, Fraisier C, Desgranges C. Cell surface phenotypic changes induced in H9T cells chronically infected with HTLV-I, HIV-1 or coinfected with the two viruses. AIDS Res Hum Retrovir 1995;11:145-54.
26. Polliack A, Gamliel H, Ben Bassat H, Gurfel D, Leizerowitz R, Minowada J. Surface morphology and membrane phenotype of cultured human leukemia-lymphoma cells. A scanning electron microscopic study of 36 cell lines. Cancer 1983;51:72-79.
27. Weiss AL, Wiskocil RL, Stobo JD. The role of T3 surface molecules inthe activation of human T cells: a two stimulus requirement for IL-2 production reflects events occuring at a pretranscriptional level. J. Immunol 1984;133:123-8.
28. Minowada J, Ohnuma T, Moore GE. Rosette-forming human lymphoid cell lines: I. Establishment and evidence for origin of thymus derived lymphocytes. J Natl Cancer Inst 1973;49:891-4.
29. Palker TJ, Tanner M, Scearce R, Streilein R, Clark M, Haynes B. Mapping of immunogenic regions of human T-cell leukemia virus type 1 (HTLV-I) gp46 and gp21 envelope glycoproteins with envencoded synthetic peptides and a monoclonal antibody to gp46. J Immunol 1989;142:971-8.
30. Gregersen JP, Mehdi S, Baur A, Hilfenhaus J. Antibody- and complement-mediated lysis of HIV-infectedcells and inhibition of viral replication. J Med Primatol 1990;30:287-93.
31. Godoy AJ, Itoyama Y, Tokunaga K, Hara H, Kawaga Y, Kiyokawa H, Maeda Y, Goto I. Allolymphocytotoxic antibodies in sera from HTLV-I-associated myelopathy-tropical spastic parapresis patients-putative anti-HLA antibodies. J Neurol Sci 1994;125:62-69.
32. Nakamura M, Kutoki M, Jun-ichi K et al. Elevated antibodies to synthetic peptides of HTLV-I envelope trasmembrane glycoproteins with TSP/HAM. J Neuroimmunol 1991;35:167-77.
33. Inoue Y, Kuroda H, Shiraki H, Sato H, Maeda Y. Neutralizing activity of human antibodies against the structural protein of human T-cell lymphotropic virus type I. Int J Cancer 1992;52:877-80.
34. Desgranges C, Souche S, Vernant JC, Smadja D, Vahlne A, Horal P. Identification of novel neutralizing-inducing regions of the human T-cell lymphotropic virus type I envelope glycoproteins with human HTLV-I seropositive sera. AIDS Res Hum Retrovir 1994;10:163-73.
35. Tanaka Y, Zeng L, Shiraki H, Tozawa H. Identification of a neutralization epitope on the envelope of gp46 antigen of human T-cell leukemia virus type I and induction of neutralizing antibody by peptides immunisation. J Immunol 1991;147:354-60.
36. Kuroki M, Nakamura M, Itoyama Y et al. Identification of new epitopes recognized by human monoclonal antibodies with neturalizing and antibody-dependent cellular cytotoxicity activities specific for human T-cell leukemia virus type I. J Immunol 1992;149:940-8.
37. Horal P, Hall WW, Svennerholm B, Lycke J, Jeansson S, Rymo L, Kaplan MH, Vahlne A. Identification of type-specific linear epitopes in the glycoprotiens gp46 and gp21 of human T-cell leukemia virus type I and type II using synthetic peptides. Proc Natl Acad Sci USA 1991;88:5754-8.
38. + human T-cell lymphotropic virus type-I-specific cytotoxic T lymphocytes from patients with HAM/TSP-recognition of an immunogenic region of the gp46 envelope glycoprotein of human T-cell lymphotropic virus type I. J Immunol 1991;146:1155-62.
39. Dalgleish A, Richardson J, Matutes E. HTLV-I infectionin tropical spastic paraparesis: lymphocyte culture and serologic response. AIDS Res Hum Retrovir 1988;6:475-85.
40. Lachman PJ. The control of homologous lysis. Immunol Today 1991;12:312-5.
41. Saifuddin M, Landry AL, Ghassemi M, Patki C, Spear GT. HTLV-I activates complement leading to increasedbinding to complement receptor-positive cells. AIDS Res Hum Retrovir 1995;11:1115-21.
42. Saarloos MN, Koenig RE, Spear GT. Elevated levels of iC3b and C4d, but not Bb, complement fragmentsfrom plasma of persons infected with human T cell leukemia virus (HTLV) with HTLV-I-associated myelopathy/tropical spastic paraparesis. J Infect Dis 1995;172:1095-7.